| Rheumatoid Arthritis

Avsola vs Celebrex

Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.
Deep comparison between: Avsola vs Celebrex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsCelebrex has a higher rate of injection site reactions vs Avsola based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Celebrex but not Avsola, including UnitedHealthcare
Sign up to reveal the full AI analysis
Avsola
Celebrex
At A Glance
IV infusion
Every 6-8 weeks
TNF-alpha inhibitor
Oral
Once or twice daily
COX-2 inhibitor
Indications
  • Crohn Disease
  • Ulcerative Colitis
  • Rheumatoid Arthritis
  • Arthritis, Psoriatic
  • Psoriasis
  • Degenerative polyarthritis
  • Rheumatoid Arthritis
  • Juvenile rheumatoid arthritis
  • Ankylosing spondylitis
  • Primary dysmenorrhea
Dosing
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks maintenance.
Rheumatoid Arthritis 3 mg/kg IV induction at weeks 0, 2, and 6, followed by 3 mg/kg every 8 weeks maintenance, in combination with methotrexate.
Ankylosing Spondylitis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 6 weeks maintenance.
Degenerative polyarthritis 200 mg once daily or 100 mg twice daily, oral.
Rheumatoid Arthritis 100 mg to 200 mg twice daily, oral.
Juvenile rheumatoid arthritis 50 mg twice daily for patients 10-25 kg; 100 mg twice daily for patients >25 kg, oral.
Ankylosing spondylitis 200 mg once daily or 100 mg twice daily, oral; if no effect after 6 weeks, may trial 400 mg daily.
Primary dysmenorrhea 400 mg initially, followed by 200 mg if needed on day 1; 200 mg twice daily on subsequent days, oral.
Contraindications
  • Doses >5 mg/kg in patients with moderate or severe heart failure
  • Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of AVSOLA, or murine proteins
  • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib or any components of the drug product
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
  • Setting of CABG surgery
  • Demonstrated allergic-type reactions to sulfonamides
Adverse Reactions
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Pneumonia, cellulitis, abscess, skin ulceration, sepsis, bacterial infection, lymphoma, hepatotoxicity
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia
Most common (>=2%) Headache, dyspepsia, upper respiratory infection, diarrhea, sinusitis, abdominal pain, nausea, back pain, peripheral edema, rhinitis, pharyngitis, rash, flatulence, dizziness, insomnia.
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity.
Postmarketing Vasculitis, deep venous thrombosis, angioedema, liver necrosis, hepatic failure, agranulocytosis, aplastic anemia, pancytopenia, aseptic meningitis, fatal intracranial hemorrhage, interstitial nephritis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, AGEP, fixed drug eruption.
Pharmacology
TNF-alpha inhibitor; chimeric IgG1kappa monoclonal antibody that neutralizes TNFalpha by binding with high affinity to the soluble and transmembrane forms of TNFalpha, inhibiting binding of TNFalpha with its receptors.
Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin synthesis in peripheral tissues and the CNS, producing analgesic, anti-inflammatory, and antipyretic effects; at therapeutic doses it does not inhibit platelet aggregation or prolong bleeding time.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Avsola
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
View full coverage details ›
Celebrex
  • Covered on 5 commercial plans
  • PA (0/12) · Step Therapy (4/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Avsola
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Celebrex
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
View full coverage details ›
Humana
Avsola
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
View full coverage details ›
Celebrex
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Avsola.
No savings programs available for Celebrex.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
AvsolaView full Avsola profile
CelebrexView full Celebrex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.